John W. Loughney - Concepedia

Author

John W. Loughney

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

John Loughney, John W Loughney, John W. Loughney

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Rutgers, The State University of New Jersey Brown Foundation

About

John W. Loughney is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, immunology, and bioanalysis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	770
2	Engineering	3	3	101
3	Biomedical Engineering	3	3	101
4	Natural Sciences	2	2	25
5	Biochemistry	2	2	29

John W. Loughney

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Shahneen Sandhu, William R. Schelman, George Wilding, The Lancet Oncology Sporadic CancerMedicineBrca Mutation CarriersPathologyCancer Treatment	2013	551
Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex Sha Ha, Fengsheng Li, Matthew C. Troutman, Journal of Virology	2017	86
Qualitative and quantitative evaluation of <scp>S</scp>imon™, a new <scp>CE</scp>‐based automated Western blot system as applied to vaccine development Richard R. Rustandi, John W. Loughney, Melissa Hamm, Electrophoresis	2012	59
Residual bovine serum albumin (BSA) quantitation in vaccines using automated Capillary Western technology John W. Loughney, Catherine Lancaster, Sha Ha, Analytical Biochemistry VaccinationVaccine DevelopmentMedicineBioanalysisImmunology	2014	58
Development of a microchip capillary electrophoresis method for determination of the purity and integrity of mRNA in lipid nanoparticle vaccines Jessica Raffaele, John W. Loughney, Richard R. Rustandi Electrophoresis EngineeringImmunologyLipid NanoparticlesFaster Vaccine DevelopmentBiomedical Engineering	2021	47
Soluble Human Cytomegalovirus gH/gL/pUL128–131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes John W. Loughney, Richard R. Rustandi, Dai Wang, Journal of Biological Chemistry	2015	44
Structure of the cell-binding component of the <i>Clostridium difficile</i> binary toxin reveals a di-heptamer macromolecular assembly Xingjian Xu, Raquel Godoy‐Ruiz, Kaylin A. Adipietro, Proceedings of the National Academy of Sciences	2020	36
Determination of lipid content and stability in lipid nanoparticles using ultra high‐performance liquid chromatography in combination with a Corona Charged Aerosol Detector Caleb Kinsey, Tian Lu, Alyssa Deiss, Electrophoresis	2021	34
Development of an imaged capillary isoelectric focusing method for characterizing the surface charge of mRNA lipid nanoparticle vaccines John W. Loughney, Kevin Minsker, Sha Ha, Electrophoresis NanoparticlesNanomedicineEngineeringNanobiotechnologyLipid Nanoparticles	2019	33
Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines Nisarg Patel, Zach Davis, Carl Hofmann, Vaccines	2023	32

Page 1